CAI Dongchen (Chairman)
Mr. Cai, aged 70, Chairman of the Company, has been an executive director of the Company since April 1997. Mr. Cai is also the chairman of the Nomination Committee and a director of certain subsidiaries of the Company. Mr. Cai holds an MBA degree from Nankai University and has extensive technical and management experience in the pharmaceutical industry.

Mr. Cai is a substantial shareholder of the Company within the meaning of Part XV of the Securities and Futures Ordinance (“SFO”). Mr. Cai is also a director of True Ally Holdings Limited and Massive Giant Group Limited, both are substantial shareholders of the Company within the meaning of Part XV of the SFO.

ZHANG Cuilong (Vice Chairman and CEO)
Mr. Zhang, aged 55, Vice-Chairman and Chief Executive Officer of the Company, has been an executive director of the Company since July 2018. Mr. Zhang is also a director of certain subsidiaries of the Company. Mr. Zhang holds a Bachelor’s degree in Pharmacology from Hebei Medical College (now known as Hebei Medical University) and has extensive technical, marketing and management experience in the pharmaceutical industry.

WANG Zhenguo
Mr. Wang, aged 54, has been an executive director of the Company since January 2012. Mr. Wang is also a director of certain subsidiaries of the Company. Mr. Wang holds a Bachelor’s degree in Chemistry from Nankai University and has extensive technical, marketing and management experience in the pharmaceutical industry.

PAN Weidong
Mr. Pan, aged 54, has been an executive director of the Company since October 2006. Mr. Pan is also a director of certain subsidiaries of the Company. Mr. Pan holds an EMBA degree from Tsinghua University and has extensive finance, accounting and investment experience in the pharmaceutical industry.

Mr. Pan is a director of Common Success International Limited, a substantial shareholder of the Company within the meaning of Part XV of the SFO.

WANG Huaiyu
Mr. Wang, aged 60, has been an executive director of the Company since October 2010. Mr. Wang is also a director of certain subsidiaries of the Company. Mr. Wang holds a Bachelor’s degree in Microbiology and Biochemistry from Hebei University and has extensive technical and management experience in the pharmaceutical industry.

LI Chunlei
Dr. Li, aged 47, has been an executive director of the Company since December 2017. Dr. Li is currently the Chief Scientist of the Group in charge of research and development. Dr. Li is also the general manager of a subsidiary of the Company, deputy director of the Novel Pharmaceutical Preparations and Excipients State Key Laboratory and director of the Hebei Pharmaceutical Engineering Technology Centre. Dr. Li holds a Bachelor’s degree in Engineering (Biological Pharmaceutics) from Jilin University and Shenyang Pharmaceutical University, a Master’s degree in Science (Microbial and Biochemical Pharmaceutics) from Jilin University and a Doctorate in Science (Pharmaceutical Science) from Shenyang Pharmaceutical University.

YAO Bing
Dr. Yao, aged 47, has been an executive director of the Company since May 2024. Dr. Yao joined the Group in July 2002 and is currently Director and General Manager of CSPC Innovation Pharmaceutical Co., Ltd., a subsidiary of the Company listed on the Shenzhen Stock Exchange, and Director of certain subsidiaries of the Company. He has been responsible for the research and development of the Group since 2017. Dr. Yao holds a Bachelor’s degree in Engineering (Biochemical Engineering), a Master’s degree in Engineering (Biochemical Engineering) and a Doctorate in Engineering (Chemical Engineering and Technology) from Nanjing Tech University, and a Master’s degree in Engineering (Project Management Engineering) from Peking University.

CAI Xin
Mr. Cai, aged 33, has been an executive director of the Company since May 2024. Mr. Cai joined the Group in March 2022. He is currently Executive President of the Group and President of the Group’s Marketing Strategy Division, mainly responsible for the sales business of the Group. Prior to joining the Group, Mr. Cai served as an analyst at CDH Investments. Mr. Cai holds a Bachelor’s degree in Science (Pharmacy) from Purdue University and a Master’s degree in Business Administration from the University of New South Wales.

CHEN Weiping
Mr. Chen, aged 45, has been an executive director of the Company since December 2024. Mr. Chen, who joined the Group in July 2004, is currently an Executive President and the General Manager of the Operation Management Centre of the Group, primarily responsible for the production operation of the Group. Mr. Chen has previously served as Workshop Director, Assistant to General Manager, Deputy General Manager and General Manager of CSPC Weisheng Pharmaceutical (Shijiazhuang) Co., Ltd., a wholly-owned subsidiary of the Company, and President of the Group's No. 2 Manufacturing Centre. Mr. Chen holds a Bachelor's degree in Engineering (Environmental Engineering) from Hebei University of Science and Technology, and is also a senior engineer and a national registered safety engineer.

WANG Bo
Mr. Wang, aged 63, has been as an independent non-executive director of the Company since December 2012. He is also a member of the Audit Committee, Nomination Committee and Remuneration Committee of the Company. Mr. Wang is currently the CEO of Beijing CHNMED Pharmaceutical Technology Development Co., Ltd and managing director of Beijing CHNMED Pharmaceutical Consulting Co., Ltd. Mr. Wang graduated from Beijing Institute of Iron and Steel and has extensive experience in pharmaceutical policy research and consulting. Mr. Wang is currently the distinguished researcher of the Research Center of National Drug Policy & Ecosystem.

Mr. Wang is also an independent director of Youcare Pharmaceutical Group Co., Ltd. (listed on Shanghai Stock Exchange).

CHEN Chuan
Mr. Chen, aged 60, has been as an independent non-executive director of the Company since June 2016. He is also a member of the Audit Committee, Nomination Committee and Remuneration Committee of the Company. Mr. Chen holds a Bachelor’s degree in Medicine from Norman Bethune University of Medical Science and a Master’s degree in Science from Albert Einstein College of Medicine at Yeshiva University.

Mr. Chen resigned as an independent director of Guangxi Liuzhou Pharmaceutical Co., Ltd. (listed on Shanghai Stock Exchange) and Shanghai Kehua Bio-Engineering Co., Ltd. (listed on Shanghai Stock Exchange) in 2023.

WANG Hongguang
Prof. Wang, aged 61, has been as an independent non-executive director of the Company since January 2021. Prof. Wang is a director and professor of International Center for Bioeconomy, Institute of Multidisciplinary Biomedical Research of Tsinghua University (National Institute of Biological Sciences, Beijing), executive director and adjunct professor of Peking University’s China Center for Strategic Studies, adjunct professor of Tianjin University and China Pharmaceutical University. Prof. Wang has previously served as a director of Center of Biotechnology Development of China of the Ministry of Science and Technology. Prof. Wang has long been engaged in the research on technology and economic strategy, and has conducted in-depth research on domestic and foreign biotechnology development and industry policies. Prof. Wang was the founder of “Disparity Economics” and has published 21 books including “Bio-economic of China” and more than 110 theses. Prof. Wang holds a Bachelor’s degree in Agriculture from Gansu Agricultural University, a Master’s degree in Agriculture and a Doctorate in Agriculture from China Agricultural University.

Prof. Wang is also an independent director of Beijing Tiantan Biological Products Corporation Limited (listed on Shanghai Stock Exchange).

AU Chun Kwok Alan
Mr. Au, aged 51, has been an independent non-executive director of the Company since January 2021. He is also the chairman of the Audit Committee and Remuneration Committee of the Company. Mr. Au is the founder and managing director of GT Healthcare Group, a private equity platform focusing on cross border healthcare investments. Prior to that, Mr. Au served as the head of the Asia Healthcare Investment Banking of Deutsche Bank Group, advising healthcare IPO and M&A in the region, an executive director at JAFCO Asia Investment Group, responsible for healthcare investments in China, and an investment director of Morningside Group in charge of healthcare investments in Asia. Mr. Au received a Bachelor’s degree in Psychology from Chinese University of Hong Kong and a Master’s degree in Management from Columbia Business School in New York. Mr. Au is a certified public accountant (CPA) in the U.S. and a chartered financial analyst (CFA), and an associate member of the Hong Kong Institute of Financial Analysts and member of the American Institute of Certified Public Accountants.

Mr. Au is also an independent director of I-Mab Biopharma Co., Ltd. (listed on Nasdaq).

LAW Cheuk Kin Stephen, JP
Mr. Law, aged 61, has been an independent non-executive director of the Company since March 2021. Mr. Law is currently the Managing Director of ANS Capital Limited. He previously served as the Finance Director and a member of the Executive Directorate of MTR Corporation Limited, CFO of Guoco Group Limited, Hong Kong and Managing Director of TPG Growth Capital (Asia) Limited, and held various senior positions in the Morningside Group and Wheelock Group. He is also a member of the board of directors of SOW (Asia) Foundation, Vice-President of the Hong Kong Institute of Certified Public Accountants, council member of Hong Kong Business Accountants Association and member of the Institute of Chartered Accountants in England and Wales. Mr. Law holds a Bachelor’s degree in Science (Civil Engineering) from the University of Birmingham, the United Kingdom and a Master’s degree in Business Administration from the University of Hull, the United Kingdom.

Mr. Law was appointed as a member of the 14th National Committee of the Chinese People’s Political Consultative Conference of the People’s Republic of China in January 2023. He has also been appointed by the Ministry of Finance of the People’s Republic of China as an expert consultant to provide advice on finance and management accounting.

Mr. Law is also an independent non-executive director of China Everbright Limited, Somerley Capital Holdings Limited, China Galaxy Securities Co., Ltd., and Keymed Biosciences Inc., all of which are listed on The Stock Exchange of Hong Kong Limited.

Li Quan
Ms. Li, aged 43, has been an independent non-executive director of the Company since November 2022. Ms. Li has over ten years of experience in investment management. She is currently the Operating Partner of CDH Investments Management (Hong Kong) Limited. Ms. Li holds a Bachelor of Cell Biology & Genetics and Economics double degree from Peking University, and a Master of Science degree from National University of Singapore School of Computing.